Immune globulin intravenous (human)-ifas - Biologic Drug Details

Summary for immune globulin intravenous (human)-ifas

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for immune globulin intravenous (human)-ifas

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for immune globulin intravenous (human)-ifas Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for immune globulin intravenous (human)-ifas Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for immune globulin intravenous (human)-ifas Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Immune Globulin Intravenous (Human)-Ifas

Last updated: February 20, 2026

What Are the Key Market Drivers for Immune Globulin Intravenous (Human) - Ifas?

The immune globulin intravenous (IGIV) market, including the product Ifas, exhibits steady growth driven by several factors:

• Increasing prevalence of immunodeficiency disorders: Primary immunodeficiency diseases (PID) and secondary immunodeficiencies linked to conditions like leukemia or HIV increase demand for IGIV products.

• Expanding clinical applications: Beyond PID, uses in autoimmune diseases such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and Kawasaki disease contribute to revenue growth.

• Rising aging populations: Older adults have higher incidences of immune-related disorders, bolstering market size.

• Enhanced product formulations: Improved purification and stabilization techniques increase safety and efficiency, supporting market expansion.

Market Size and Growth Rate:

• The global IGIV market size was valued at approximately USD 7.5 billion in 2022.
• Compound annual growth rate (CAGR) is projected at 6.5% from 2023 to 2030 (Grand View Research, 2022).

What Is the Financial Trajectory of Ifas?

Although specific revenue data for Ifas remains proprietary, market analysts forecast:

• Revenue estimation: The broader IGIV segment is expected to grow from USD 7.5 billion in 2022 to over USD 13 billion by 2030.
• Market share assumptions: Ifas’s share correlates with its approval status, manufacturing capacity, and clinical positioning. Assuming it captures 2–5% of the market, revenues may range from USD 150 million to USD 650 million by 2030.
• Pricing trends: Stable or slightly increased prices are expected due to manufacturing complexities and quality standards, especially for higher purity formulations.

How Do Regulatory and Competitive Factors Affect the Market?

• Regulatory clearance: US FDA approval and European EMA licensing influence market access. Any delays can hinder revenue growth.
• Competition: Several players dominate, including CSL Behring, Grifols, and Takeda. Market entry for new or incremental products like Ifas depends on differentiation and clinical evidence.
• Manufacturing complexity: Plasma collection and purification are resource-intensive, impacting gross margins and scalability.

What Are the Challenges and Opportunities?

Challenges:

• Supply constraints tied to plasma donor availability.
• Price pressures driven by payer negotiations and reimbursement policies.
• Stringent regulatory standards increase operational costs.

Opportunities:

• Development of next-generation formulations with longer half-life.
• Expansion into orphan disease markets with unmet needs.
• Collaborations with biotech firms for innovative delivery mechanisms.

How Does the Financial Outlook Compare Globally?

Regional variances influence revenue potential:

Region	Market Size (USD Billion, 2022)	CAGR (2023-2030)	Key Factors
North America	3.5	6.0%	High prevalence of immunodeficiency, favorable reimbursement policies
Europe	2.2	6.8%	Growing aging population, robust healthcare infrastructure
Asia-Pacific	1.0	8.5%	Rapid economic growth, increasing diagnosis rates
Rest of World	0.8	6.5%	Emerging markets with expanding healthcare access

What Are the Key Trends Affecting the Market and Financial Outlook?

• Biological innovations: Long-acting formulations aim to reduce dosing frequency and improve patient compliance.
• Manufacturing advancements: Recombinant technology introduction may alter supply chains.
• Policy shifts: Reimbursement reforms influence pricing strategies.
• Market consolidation: Mergers and acquisitions can reshape competitive dynamics and influence product portfolios.

Key Takeaways

• The IGIV segment, including Ifas, is projected to grow at a CAGR of approximately 6.5% through 2030.
• Revenue potential for Ifas hinges on approval success, market share acquisition, and regional adoption.
• Supply chain constraints and regulatory challenges remain significant barriers.
• Innovation in formulations and expanding indications present future growth opportunities.
• Regional disparities influence market size and rate of growth.

FAQs

1. When is Ifas expected to reach peak sales?
   Peak sales timing depends on regulatory approval and market penetration strategies, likely between 2025 and 2028.

2. How does plasma donor availability impact Ifas’s supply chain?
   Plasma availability directly influences manufacturing capacity, with shortages potentially limiting sales growth.

3. Will biosimilars threaten Ifas’s market share?
   Biosimilars could enter the market post-patent expiry, increasing competition and influencing pricing.

4. What role will emerging markets play in Ifas’s revenue growth?
   Rapid expansion in Asia-Pacific and Latin America can significantly augment global sales, especially with increasing healthcare infrastructure.

5. Are there any regulatory hurdles specific to Ifas?
   Regulatory approval will depend on demonstrating safety, efficacy, and manufacturing quality aligning with regional standards.

---

References

[1] Grand View Research. (2022). Immune Globulin Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2022). Regulatory considerations for plasma-derived medicinal products.